Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: Outcome dependent on in vitro selection protocol

PLoS Neglected Tropical Diseases

Volumn 6, Issue 5, 2012, Pages

  Hendrickx, Sarah ^a   Inocêncio da Luz, Raquel Andrea ^a   Bhandari, Vasundhra ^b   Kuypers, Kristel ^a   Shaw, Craig D ^c   Lonchamp, Julien ^c   Salotra, Poonam ^b   Carter, Katharine ^c   Sundar, Shyam ^d   Rijal, Suman ^e   Dujardin, Jean Claude ^f   Cos, Paul ^a   Maes, Louis ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b SAFDARJUNG HOSPITAL   (India)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d BANARAS HINDU UNIVERSITY   (India)

^e B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^f INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; PAROMOMYCIN; ANTIPROTOZOAL AGENT;

AMASTIGOTE; ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLONING; CONTROLLED STUDY; IC 50; IN VITRO STUDY; INDIA; LEISHMANIA DONOVANI; MOUSE; NEPAL; NONHUMAN; PHENOTYPE; PROMASTIGOTE; SYRIAN HAMSTER; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECT; DRUG RESISTANCE; DRUG SENSITIVITY; GENETIC SELECTION; GENOMIC INSTABILITY; HAMSTER; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; PARASITOLOGY; VIRUS CULTURE; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; CRICETINAE; DRUG RESISTANCE; GENOMIC INSTABILITY; HUMANS; INDIA; INHIBITORY CONCENTRATION 50; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MESOCRICETUS; MICE; MICE, INBRED BALB C; NEPAL; PARASITIC SENSITIVITY TESTS; PARASITOLOGY; PAROMOMYCIN; SELECTION, GENETIC; SERIAL PASSAGE;

EID: 84863711529     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001664     Document Type: Article

References (30)

1. Sundar S, Chatterjee M, (2006) Visceral leishmaniasis- current therapeutic modalities. Indian J Med Res 123: 345-352.
2. WHO Regional Office for South-East Asia: www.searo.who.int/en/Section10/Section2163_11676.htm. Accessed Feb 2012.
3. Dhillon GP, Sharma SN, Nair B, (2008) Kala-azar elimination programme in India. J Indian Med Assoc 106: 664-666.
4. Davidson RN, den Boer M, Ritmeijer K, (2009) Paromomycin. Trans R Soc Trop Med Hyg 103: 653-660.
5. van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, et al. (2010) Combination therapy for visceral leishmaniasis. Lancet Infect Dis 10: 184-194.
6. Sundar S, Chakravarty J, (2008) Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs 17: 787-794.
7. Kulshrestha A, Singh R, Kumar D, Negi NS, Salotra P, (2011) Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine. Antimicrob Agents Chemother 55: 2916-2921.
8. Maarouf M, de Kouchkovsky Y, Brown S, Petit PX, Robert-Gero M, (1997) In vivo interference of paromomycin with mitochondrial activity of Leishmania. Exp Cell Res 232: 339-348.
9. Jhingran A, Chawla B, Saxena S, Barrett MP, Madhubala R, (2009) Paromomycin: uptake and resistance in Leishmania donovani. Mol Biochem Parasitol 164: 111-117.
10. Maarouf M, Adeline MT, Solignac M, Vautrin D, Robert-Gero M, (1998) Development and characterization of paromomycin-resistant Leishmania donovani promastigotes. Parasite 5: 167-173.
11. Croft SL, Sundar S, Fairlamb AH, (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111-126.
12. Maes L, Vanden Berghe D, Germonprez N, Quirijnen L, Cos P, et al. (2004) In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral leishmania species. Antimicrob Agents Chemother 48: 130-136.
13. Quispe Tintaya KW, Ying X, Dedet JP, Rijal S, De Bolle X, et al. (2004) Antigen genes for molecular epidemiology of leishmaniasis: polymorphism of cysteine proteinase B and surface metalloprotease glycoprotein 63 in the Leishmania donovani complex. J Infect Dis 189: 1035-1043.
14. da Luz RI, Vermeersch M, Dujardin JC, Cos P, Maes L, (2009) In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells. Antimicrob Agents Chemother 53: 5197-5203.
15. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK, (2007) Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356: 2571-2581.
16. Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Zaniewski AE, et al. (2000) A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 94: 429-431.
17. Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, et al. (2007) Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg 77: 89-94.
18. Murray HW, (2010) Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India. Future Microbiol 5: 1301-1303.
19. Jha TK, (2006) Drug unresponsiveness & combination therapy for kala-azar. Indian J Med Res 123: 389-398.
20. Thornton SJ, Wasan KM, Piecuch A, Lynd LL, Wasan EK, (2010) Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan. Drug Dev Ind Pharm 36: 1312-1319.
21. Musa AM, Younis B, Fadlalla A, Royce C, Balasegaram M, et al. (2010) Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl Trop Dis 4: e855.
22. Brotherton MC, Racine G, Foucher AL, Drummelsmith J, Papadopoulou B, et al. (2010) Analysis of stage-specific expression of basic proteins in Leishmania infantum. J Proteome Res 9: 3842-3853.
23. Chakraborty B, Biswas S, Mondal S, Bera T, (2010) Stage specific developmental changes in the mitochondrial and surface membrane associated redox systems of Leishmania donovani promastigote and amastigote. Biochemistry (Mosc) 75: 494-518.
24. Holzer TR, McMaster WR, Forney JD, (2006) Expression profiling by whole-genome interspecies microarray hybridization reveals differential gene expression in procyclic promastigotes, lesion-derived amastigotes, and axenic amastigotes in Leishmania mexicana. Mol Biochem Parasitol 146: 198-218.
25. Vermeersch M, da Luz RI, Toté K, Timmermans JP, Cos P, et al. (2009) In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother 53: 3855-3859.
26. t'Kindt R, Scheltema RA, Jankevics A, Brunker K, Rijal S, et al. (2010) Metabolomics to unveil and understand phenotypic diversity between pathogen populations. PLoS Negl Trop Dis 4: e904.
27. Zheng L, t'Kind R, Decuypere S, von Freyend SJ, Coombs GH, et al. (2010) Profiling of lipids in Leishmania donovani using hydrophilic interaction chromatography in combination with Fourier transform mass spectrometry. Rapid Commun Mass Spectrom 2010 24: 2074-2082.
28. Mukhopadhyay R, Mukherjee S, Mukherjee B, Naskar K, Mondal D, et al. (2011) Characterisation of antimony-resistant Leishmania donovani isolates: Biochemical and biophysical studies and interaction with host cells. Int J Parasitol 41: 1311-1321.
29. Cos P, Toté K, Horemans T, Maes L, (2010) Biofilms: an extra hurdle for effective antimicrobial therapy. Curr Pharm Des 16: 2279-2295.
30. Coelho AC, Boisvert S, Mukherjee A, Leprohon P, Corbeil J, et al. (2012) Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing. PLoS Negl Trop Dis pp. e1512 Epub Feb 14.